Current status and prospect of immunotherapy for cholangiocarcinoma
10.3760/cma.j.cn115610-20220506-00254
- VernacularTitle:胆管癌免疫治疗的现状与展望
- Author:
Shi ZUO
1
;
Qian CHEN
;
Weilong ZOU
Author Information
1. 贵州医科大学附属医院肝胆外科,贵阳 550004
- Keywords:
Bile tract neoplasms;
Immunotherapy;
Immune checkpoint inhibitors;
Tumor microenvironment;
Adoptive cell therapy;
Tumor vaccine
- From:
Chinese Journal of Digestive Surgery
2022;21(7):873-879
- CountryChina
- Language:Chinese
-
Abstract:
Cholangiocarcinoma (CCA) is a category of highly heterogeneous and aggressive malignancy mainly originating from bile duct epithelial cells. The median survival time of untreated CCA patients is approximately 12?24 months, and the effectiveness and durability of surgical resection and neoadjuvant chemotherapy are limited. Results of the next-generation sequencing show that dysregulation of the immune system plays an important role in the pathogenesis of CCA. It has opened up new possibilities for the study of therapies targeting the natural course of aggressive CCA, such as immune checkpoint inhibitors, adoptive cell therapy, and tumor vaccines. Based on the current status of immunotherapy for CCA, the authors review the efficacy and dilemmas of current CCA immunotherapy strategies and look forward to the future treatment prospects of CCA.